Bright Minds Biosciences Inc

DRUG is in a Stage 4 decline with price below all major EMAs and the 50-DMA. Recent bounce into moving averages has not reclaimed resistance and underscores seller control. Intermediate structure favors further downside, but short-term timing is neutral due to oversold conditions. Selling into EMA and DMA resistance zones remains the preferred approach, with a decisive break above the 21-EMA and 50-DMA on strong volume required to invalidate the bearish thesis.

• ↑High institutional ownership suggests robust buying interest from 13F filings
• ↑Analyst consensus rating Buy (3.14) with $143.83 price target implies +88% upside
• ↓Negative earnings yield and weak profitability factors signal cash burn